Standout Papers

Angiogenesis as a therapeutic target 2002 2026 2010 2018 2.1k
  1. Angiogenesis as a therapeutic target (2005)
    Napoleone Ferrara, Robert S. Kerbel Nature
  2. Tumor Angiogenesis (2008)
    Robert S. Kerbel New England Journal of Medicine
  3. Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis (2009)
    John M.L. Ebos, Christina R. Lee et al. Cancer Cell
  4. Clinical translation of angiogenesis inhibitors (2002)
    Robert S. Kerbel, Judah Folkman Nature reviews. Cancer
  5. The anti-angiogenic basis of metronomic chemotherapy (2004)
    Robert S. Kerbel, Barton A. Kamen Nature reviews. Cancer
  6. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity (2000)
    Giannoula Klement, Sylvain Baruchel et al. Journal of Clinical Investigation
  7. Establishment and Characterization of First Trimester Human Trophoblast Cells with Extended Lifespan (1993)
    Charles H. Graham, Teresa S. Hawley et al. Experimental Cell Research
  8. β1-6 Branching of Asn-Linked Oligosaccharides Is Directly Associated with Metastasis (1987)
    James W. Dennis, Suzanne Laferté et al. Science
  9. Tumor angiogenesis: past, present and the near future (2000)
    Robert S. Kerbel Carcinogenesis
  10. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. (1997)
    Janusz Rak, Mien‐Chie Hung et al. PubMed
  11. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. (1995)
    Janusz Rak, Yoshihiro Mitsuhashi et al. PubMed
  12. Antiangiogenic therapy in oncology: current status and future directions (2016)
    Gordon C. Jayson, Robert S. Kerbel et al. The Lancet
  13. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR (2009)
    Khalid Al‐Nedawi, Brian Meehan et al. Proceedings of the National Academy of Sciences
  14. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis (2011)
    John M.L. Ebos, Robert S. Kerbel Nature Reviews Clinical Oncology
  15. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa (2018)
    Kabir A. Khan, Robert S. Kerbel Nature Reviews Clinical Oncology
  16. Vessel co-option in cancer (2019)
    Elizabeth A. Kuczynski, Peter Vermeulen et al. Nature Reviews Clinical Oncology

Immediate Impact

14 by Nobel laureates 62 from Science/Nature 265 standout
Sub-graph 1 of 18

Citing Papers

Tumour vasculature at single-cell resolution
2024 StandoutNature
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
2017 StandoutNature
82 intermediate papers

Works of Robert S. Kerbel being referenced

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
2009 Standout
Clinical translation of angiogenesis inhibitors
2002 Standout
and 63 more

Author Peers

Author Last Decade Papers Cites
Robert S. Kerbel 24243 16351 13246 398 41.1k
Isaiah J. Fidler 21725 20990 13490 496 47.8k
Amato J. Giaccia 22859 10629 17174 346 39.7k
Daniel J. Hicklin 20563 13904 8709 184 34.9k
Kornélia Polyák 29875 26258 14562 198 48.9k
Daniel D. Von Hoff 19391 23213 8189 816 43.9k
Max S. Wicha 21955 28655 12424 289 42.6k
Anirban Maitra 26073 25265 14142 557 50.0k
David A. Tuveson 19285 20810 9180 200 40.1k
Charles Swanton 12617 12369 12292 314 29.4k
Harold L. Moses 24171 14456 6445 311 40.1k

All Works

Loading papers...

Rankless by CCL
2026